Healx utilizes generative AI to enhance and combine existing compounds for the rapid discovery of treatments for rare diseases, addressing the lack of effective therapies for over 90% of the 10,000 known rare diseases. By de-risking the drug development process, Healx increases the likelihood of successful outcomes and accelerates the delivery of new therapies to patients.
Funding
$47M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Over 90% of the 10,000 known rare diseases lack effective therapies, leaving 300 million people worldwide without adequate treatment options. Traditional drug discovery methods are slow, expensive, and have a low success rate, disincentivizing pharmaceutical companies from investing in rare disease treatments.
Solution
Healx leverages artificial intelligence (AI) to identify and enhance existing compounds for the rapid development of treatments for rare diseases. The company's AI platform analyzes complex data to find novel drug-disease relationships and predict the likelihood of treatment success. By focusing on drug redevelopment, combination therapies, and known compounds, Healx de-risks the drug discovery process, accelerates the development timeline, and increases the probability of delivering effective therapies to patients. This approach allows for parallel program execution and a higher chance of treatment success, addressing the significant unmet needs in the rare disease community.
Target Audience
Healx's primary target audience includes rare disease patients, patient advocacy groups, pharmaceutical companies, and clinical researchers focused on developing treatments for rare genetic disorders.
Features
- AI-driven platform for identifying novel drug-disease relationships
- Focus on drug redevelopment, combination, and enhancement of known compounds
- Scalable drug pipeline to deliver significant patient impact
- HLX-1502: Phase 2 trial for Neurofibromatosis Type 1 (NF1)
- HLX-0213: Preclinical program for Neurofibromatosis Type 1 (NF1)
- HLX-0206: Preclinical program for Fragile X Syndrome
- HLX-0553: Preclinical program for Angelman Syndrome
- HLX-2607: Preclinical program for Autosomal Dominant Polycystic Kidney Disease